Ho CL - Search Results

1

Development of a novel ALK rearrangement screening test for non-small cell lung cancers.

Chen YL, Chen WL, Cheng YC, Lin MC, Yang SC, Tsai HW, Lin CC, Su WC, Chow NH, Ho CL. Chen YL, et al. Among authors: ho cl. PLoS One. 2021 Sep 24;16(9):e0257152. doi: 10.1371/journal.pone.0257152. eCollection 2021. PLoS One. 2021. PMID: 34559836 Free PMC article.

2

Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation.

Cheng HL, Trink B, Tzai TS, Liu HS, Chan SH, Ho CL, Sidransky D, Chow NH. Cheng HL, et al. Among authors: ho cl. J Clin Oncol. 2002 Mar 15;20(6):1544-50. doi: 10.1200/JCO.2002.20.6.1544. J Clin Oncol. 2002. PMID: 11896103

3

Clinical significance of allelotype profiling for urothelial carcinoma.

Tzai TS, Chen HH, Chan SH, Ho CL, Tsai YS, Cheng HL, Dai YC, Lin JS, Yang WH, Chow NH. Tzai TS, et al. Among authors: ho cl. Urology. 2003 Aug;62(2):378-84. doi: 10.1016/s0090-4295(03)00344-3. Urology. 2003. PMID: 12893368

4

Allelic loss of 14q32 in the pathogenesis of gastrointestinal and ampullary malignancies: mapping of the target region to a 17 cM interval.

Dai YC, Ho CL, Tsai YC, Hsu YH, Chang YC, Liu HS, Chen HH, Chow NH. Dai YC, et al. Among authors: ho cl. J Cancer Res Clin Oncol. 2005 Feb;131(2):94-100. doi: 10.1007/s00432-004-0622-3. Epub 2004 Oct 21. J Cancer Res Clin Oncol. 2005. PMID: 15503134

5

The novel targets for anti-angiogenesis of genistein on human cancer cells.

Su SJ, Yeh TM, Chuang WJ, Ho CL, Chang KL, Cheng HL, Liu HS, Cheng HL, Hsu PY, Chow NH. Su SJ, et al. Among authors: ho cl. Biochem Pharmacol. 2005 Jan 15;69(2):307-18. doi: 10.1016/j.bcp.2004.09.025. Epub 2004 Nov 19. Biochem Pharmacol. 2005. PMID: 15627483

6

Mini chamber system for long-term maintenance and observation of cultured cells.

Ho CL, Mou TY, Chiang PS, Weng CL, Chow NH. Ho CL, et al. Biotechniques. 2005 Feb;38(2):267-73. doi: 10.2144/05382RR03. Biotechniques. 2005. PMID: 15727133 Free article.

7

The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma.

Tsai HW, Chow NH, Lin CP, Chan SH, Chou CY, Ho CL. Tsai HW, et al. Among authors: ho cl. Hum Pathol. 2006 Feb;37(2):198-204. doi: 10.1016/j.humpath.2005.10.012. Epub 2005 Dec 20. Hum Pathol. 2006. PMID: 16426920

8

Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis.

Hsu PY, Liu HS, Cheng HL, Tzai TS, Guo HR, Ho CL, Chow NH. Hsu PY, et al. Among authors: ho cl. J Urol. 2006 Nov;176(5):2262-7. doi: 10.1016/j.juro.2006.07.048. J Urol. 2006. PMID: 17070309

9

The molecular signature for urothelial carcinoma of the upper urinary tract.

Ho CL, Tzai TS, Chen JC, Tsai HW, Cheng HL, Eisenberger CF, Chow NH. Ho CL, et al. J Urol. 2008 Mar;179(3):1155-9. doi: 10.1016/j.juro.2007.10.026. J Urol. 2008. PMID: 18206169

10

Immunohistochemical detection of prostate-specific antigen expression in primary urothelial carcinoma of the urinary bladder.

Chen JC, Ho CL, Tsai HW, Tzai TS, Liu HS, Chow NH, Yang WH, Cheng HL. Chen JC, et al. Among authors: ho cl. Anticancer Res. 2008 Nov-Dec;28(6B):4149-54. Anticancer Res. 2008. PMID: 19192675 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

812 results

Search Page

Filters